X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with STC INDIA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs STC INDIA - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

STC INDIA 
   Change

Set up in 1956, State Trading Corporation of India Ltd. (STCIL) is a state-owned company engaged in the business of trading bulk commodities like foodgrains, edible oil, fertilizers, chemicals, pharmaceuticals, hydro-carbons, minerals. The company pl... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES STC INDIA INDOCO REMEDIES/
STC INDIA
 
P/E (TTM) x 22.6 -5.9 - View Chart
P/BV x 2.7 0.9 300.8% View Chart
Dividend Yield % 0.8 0.0 -  

Financials

 INDOCO REMEDIES   STC INDIA
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
STC INDIA
Mar-15
INDOCO REMEDIES/
STC INDIA
5-Yr Chart
Click to enlarge
High Rs360186 193.9%   
Low Rs249140 177.9%   
Sales per share (Unadj.) Rs119.02,415.7 4.9%  
Earnings per share (Unadj.) Rs8.44.4 191.6%  
Cash flow per share (Unadj.) Rs15.27.7 197.8%  
Dividends per share (Unadj.) Rs1.600-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs70.7173.2 40.8%  
Shares outstanding (eoy) m92.1560.00 153.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.60.1 3,795.8%   
Avg P/E ratio x36.437.3 97.6%  
P/CF ratio (eoy) x20.021.2 94.6%  
Price / Book Value ratio x4.30.9 458.0%  
Dividend payout %19.10-   
Avg Mkt Cap Rs m28,0839,777 287.2%   
No. of employees `0006.00.7 817.9%   
Total wages/salary Rs m2,1671,004 215.8%   
Avg. sales/employee Rs Th1,817.0196,395.8 0.9%   
Avg. wages/employee Rs Th359.01,360.6 26.4%   
Avg. net profit/employee Rs Th127.7354.9 36.0%   
INCOME DATA
Net Sales Rs m10,968144,940 7.6%  
Other income Rs m402,415 1.6%   
Total revenues Rs m11,007147,355 7.5%   
Gross profit Rs m1,565-301 -519.3%  
Depreciation Rs m633200 316.1%   
Interest Rs m621,578 3.9%   
Profit before tax Rs m909336 270.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m011 0.0%   
Extraordinary Inc (Exp) Rs m0-33 0.0%   
Tax Rs m13952 266.2%   
Profit after tax Rs m771262 294.3%  
Gross profit margin %14.3-0.2 -6,862.4%  
Effective tax rate %15.315.5 98.4%   
Net profit margin %7.00.2 3,888.9%  
BALANCE SHEET DATA
Current assets Rs m5,72524,977 22.9%   
Current liabilities Rs m5,45421,752 25.1%   
Net working cap to sales %2.52.2 110.9%  
Current ratio x1.01.1 91.4%  
Inventory Days Days620 44,919.6%  
Debtors Days Days7261 117.5%  
Net fixed assets Rs m5,3079,599 55.3%   
Share capital Rs m184600 30.7%   
"Free" reserves Rs m6,3319,789 64.7%   
Net worth Rs m6,51610,389 62.7%   
Long term debt Rs m1,3231,763 75.1%   
Total assets Rs m11,97046,589 25.7%  
Interest coverage x15.61.2 1,289.8%   
Debt to equity ratio x0.20.2 119.7%  
Sales to assets ratio x0.93.1 29.5%   
Return on assets %7.03.9 176.2%  
Return on equity %11.82.5 469.2%  
Return on capital %12.415.6 79.6%  
Exports to sales %00.9 0.0%   
Imports to sales %077.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA111,860 0.0%   
Fx inflow Rs m4,5071,264 356.6%   
Fx outflow Rs m1,141111,912 1.0%   
Net fx Rs m3,366-110,648 -3.0%   
CASH FLOW
From Operations Rs m886244 363.7%  
From Investments Rs m-1,706166 -1,029.3%  
From Financial Activity Rs m1,316-926 -142.2%  
Net Cashflow Rs m497-516 -96.2%  

Share Holding

Indian Promoters % 59.2 90.0 65.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 2.0 625.0%  
FIIs % 6.0 0.2 3,000.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 7.9 283.5%  
Shareholders   12,805 27,829 46.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   COMMEX TECHNOLOGY  KOTHARI PRODUCTS  NESCO LIMITED  JSW HOLDINGS  RELIGARE ENT.  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 23, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS